Advik Laboratories' Rights Issue Stayed By Delhi HC | All You Need To Know

A Delhi court has put Advik Laboratories' proposed rights issue on hold after a shareholder moved the court with allegations linked to the company's affairs and earlier fund-raising exercises. The order has temporarily stopped the company from moving ahead with key steps in the issue until the dispute is examined further.

The petition was filed by Fairplan Distributors Pvt. Ltd., described as a significant shareholder in Advik Laboratories. The company sought urgent intervention from the Patiala House Courts, arguing that the proposed rights issue should not proceed before the court considers its concerns. The allegations have not yet been tested or adjudicated by the court.

Delhi court restrains Advik Laboratories rights issue

The Patiala House Courts granted an ad-interim ex parte injunction after observing that a prima facie case had been made out. An ex parte order means the court passed interim relief at this stage without hearing all parties in full. Such orders are usually temporary and remain subject to further submissions by the defendants.

Under the court's direction, Advik Laboratories and certain defendants have been restrained from progressing with the proposed fund-raising exercise. The restriction covers regulatory filings, circulation of offer documents, acceptance of subscriptions and allotment of shares. These are critical stages in any rights issue, and the order effectively pauses the transaction.

Fairplan Distributors argued that allowing the issue to proceed could lead to irreversible consequences before the dispute is adjudicated. In shareholder disputes, courts often assess whether a proposed corporate action could alter ownership, voting strength or financial rights before the parties receive a full hearing.

The matter is now expected to move to the next stage of litigation. Vikas Garg and the other defendants are expected to file their responses and seek appropriate relief before the court. The case is scheduled for further hearing on August 22, 2026. Until then, the proposed rights issue remains on hold.

What a rights issue means for shareholders

A rights issue allows a company to raise capital by offering additional shares to existing shareholders, usually in proportion to their current holdings. The offer is often made at a fixed price and within a defined subscription period. Shareholders may subscribe, renounce their entitlement, or allow the offer to lapse, depending on the terms.

For companies, rights issues can be a useful way to strengthen capital, repay debt, fund expansion or meet working capital requirements. For shareholders, however, such offers can have a direct impact on ownership percentage. If an investor does not participate, their stake may be diluted once new shares are allotted.

This is why disputes around rights issues can become sensitive, especially in companies where shareholding patterns, management control or prior capital use are under question. A court stay does not decide the merits of the allegations. It only preserves the position until the court has an opportunity to examine the case further.

In this case, Fairplan Distributors has raised concerns over the utilisation of funds from earlier capital-raising exercises and alleged corporate governance lapses. These allegations remain pending before the court. Advik Laboratories and the other defendants will have the opportunity to respond when the matter is heard further.

Investor focus shifts to governance and disclosure
The court's intervention places immediate attention on governance, disclosure and board-level decision-making at Advik Laboratories. For listed companies, fund-raising decisions are closely watched because they affect share capital, investor rights and market confidence. Any delay or legal challenge can also influence how minority shareholders assess risk.

For market participants, the key issue is not only the stay itself but the questions it raises about process. Investors generally look for clarity on why fresh capital is being raised, how earlier funds were used, whether approvals were properly obtained, and whether the terms are fair to all shareholders.

The stay also means that investors who were tracking the rights issue will have to wait for the next court developments. Until the court modifies, vacates or extends the injunction, the company cannot proceed with the restrained stages of the process. Any further action will depend on the court's directions.

Advik Laboratories shares showed little immediate movement after the development. At 2:35 PM, the stock was flat at ₹1.81 apiece on the BSE. The muted price reaction suggests investors may be waiting for formal responses from the company and further clarity from the court proceedings.

The dispute now rests on the next round of pleadings and judicial scrutiny. The temporary stay protects the status quo, while leaving the allegations open for examination. For shareholders, the August 22, 2026 hearing will be the next important milestone in determining whether the proposed rights issue can move forward.